JP2015516452A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516452A5
JP2015516452A5 JP2015511958A JP2015511958A JP2015516452A5 JP 2015516452 A5 JP2015516452 A5 JP 2015516452A5 JP 2015511958 A JP2015511958 A JP 2015511958A JP 2015511958 A JP2015511958 A JP 2015511958A JP 2015516452 A5 JP2015516452 A5 JP 2015516452A5
Authority
JP
Japan
Prior art keywords
pain
weeks
refers
treated
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015511958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516452A (ja
JP6116679B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/001471 external-priority patent/WO2013170972A1/en
Publication of JP2015516452A publication Critical patent/JP2015516452A/ja
Publication of JP2015516452A5 publication Critical patent/JP2015516452A5/ja
Application granted granted Critical
Publication of JP6116679B2 publication Critical patent/JP6116679B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015511958A 2012-05-18 2013-05-16 (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよび抗けいれん剤を含む医薬組成物 Active JP6116679B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12003898 2012-05-18
EP12003898.9 2012-05-18
EP13159330.3 2013-03-15
EP13159330 2013-03-15
PCT/EP2013/001471 WO2013170972A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an anticonvulsant

Publications (3)

Publication Number Publication Date
JP2015516452A JP2015516452A (ja) 2015-06-11
JP2015516452A5 true JP2015516452A5 (https=) 2017-03-09
JP6116679B2 JP6116679B2 (ja) 2017-04-19

Family

ID=48446244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511958A Active JP6116679B2 (ja) 2012-05-18 2013-05-16 (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよび抗けいれん剤を含む医薬組成物

Country Status (20)

Country Link
US (1) US9345689B2 (https=)
EP (1) EP2852384B1 (https=)
JP (1) JP6116679B2 (https=)
CN (1) CN104284656A (https=)
AU (1) AU2013262078B2 (https=)
CA (1) CA2873871A1 (https=)
CY (1) CY1118634T1 (https=)
DK (1) DK2852384T3 (https=)
EA (1) EA029767B1 (https=)
ES (1) ES2624220T3 (https=)
HR (1) HRP20170517T1 (https=)
HU (1) HUE031984T2 (https=)
IL (1) IL235654A (https=)
LT (1) LT2852384T (https=)
MX (1) MX353177B (https=)
PL (1) PL2852384T3 (https=)
PT (1) PT2852384T (https=)
RS (1) RS55905B1 (https=)
SI (1) SI2852384T1 (https=)
WO (1) WO2013170972A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6673924B2 (ja) 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および/または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
EP3419621A4 (en) * 2016-02-26 2019-10-30 The Johns Hopkins University PHARMACOLOGICAL MODULATORS OF NAV1.1 VOLTAGE-CONTROLLED SODIUM CHANNELS ASSOCIATED WITH MECHANICAL PAIN
WO2017195144A1 (en) * 2016-05-12 2017-11-16 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
MA51978A (fr) * 2016-12-06 2021-01-20 Hesselink Jan Marius Keppel Phénytoïne à usage topique destinée a être utilisée dans le traitement de la douleur neuropathique périphérique
US20210161808A1 (en) * 2018-07-24 2021-06-03 Zenvision Pharma Llp Nasal Drug Delivery System of Brivaracetam or Salt Thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2006514934A (ja) 2002-11-26 2006-05-18 アレックザ ファーマシューティカルズ, インコーポレイテッド 疼痛治療用薬剤製造のためのロキサピンまたはアモキサピンの使用
US20040222123A1 (en) * 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CN1245379C (zh) 2003-10-30 2006-03-15 曹桂东 加巴喷丁的制法
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2008501778A (ja) 2004-06-09 2008-01-24 ファイザー・インク 疼痛の治療のためのレボキセチンの使用
GB0412878D0 (en) 2004-06-09 2004-07-14 Pfizer Ltd Use
US8093408B2 (en) 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US20080014264A1 (en) 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
JP2008106028A (ja) * 2006-10-26 2008-05-08 Boehringer Ingelheim Internatl Gmbh 慢性疼痛の治療におけるフリバンセリンの使用
US20080153874A1 (en) 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
WO2008108639A1 (en) 2007-03-08 2008-09-12 Avantium Holding B.V. Co-crystalline forms of carbamazepine
EP1977744A1 (en) 2007-04-03 2008-10-08 Chemo Ibérica, S.A. Polymorphic Form alpha of (S)-Pregabalin and process for its preparation
MX2010006608A (es) * 2007-12-21 2010-10-05 Paz Arzneimittelentwicklung Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor.
WO2009146325A1 (en) 2008-05-28 2009-12-03 Pliva Hrvatska D.O.O. Polymorphic and amorphous forms of lacosamide and amorphous compositions
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀과 항간질제의 약제학적 병용물
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
AU2011287952B2 (en) * 2010-08-04 2014-08-21 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane- 1,1'-pyrano[3,4,b]indol]-4-amine
WO2012016703A2 (en) * 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
KR20130097173A (ko) * 2010-08-04 2013-09-02 그뤼넨탈 게엠베하 신경병증성 통증을 치료하기 위한 6’­플루오로­(N­메틸­ 또는 N,N­디메틸­)­4­페닐­4’,9’­디하이드로­3’H­스피로[사이클로헥산­1,1’­피라노[3,4,b]인돌]­4­아민을 포함하는 약제학적 투여형

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
HRP20200600T1 (hr) Tapentadol za sprječavanje i liječenje depresije i tjeskobe
JP2016518337A5 (https=)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
JP2010222367A5 (https=)
JP2016053040A5 (https=)
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
JP2015523407A5 (https=)
JP2015057451A5 (https=)
JP2015516452A5 (https=)
JP2016512817A5 (https=)
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
HRP20241716T1 (hr) Postupci liječenja promjena u ponašanju
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
CN110062628A (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
JP2015516450A5 (https=)
JP2017513944A5 (https=)
JP2015516449A5 (https=)
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
JP2015516451A5 (https=)
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
ECSP15025868A (es) Composición que comprende un extracto purificado aíslado de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir/tratar la enfermedad pulmonar obstructiva crónica, y su uso